Trial Profile
A Phase I/II, Open-Label, Escalating Dose, "Optimal Two-Stage", Study of TNFalpha-Kinoid (TNF- K) Immunization in Crohn's Disease Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tumour necrosis factor-alpha kinoid (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- 02 May 2011 Results will be presented at Digestive Disease Week, according to a Neovacs media release.
- 12 Jan 2011 Results were reported in an oral presentation at the 2011 European Crohn's and Colitis Organisation (ECCO).
- 08 Dec 2010 Results were reported in a Neovacs media release.